Share on StockTwits

Coronado Biosciences (NASDAQ:CNDO) CFO Lucy Lu purchased 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 2nd. The shares were purchased at an average price of $1.37 per share, with a total value of $6,850.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,631 shares of the company’s stock, valued at approximately $41,964. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Coronado Biosciences (NASDAQ:CNDO) opened at 1.70 on Friday. Coronado Biosciences has a 52-week low of $1.25 and a 52-week high of $10.20. The stock’s 50-day moving average is $1.72 and its 200-day moving average is $2.16. The company’s market cap is $75.3 million.

Coronado Biosciences (NASDAQ:CNDO) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.20) by $0.01. Analysts expect that Coronado Biosciences will post $-0.75 EPS for the current fiscal year.

Separately, analysts at Zacks downgraded shares of Coronado Biosciences from an “outperform” rating to a “neutral” rating in a research note on Wednesday, March 12th. They now have a $3.10 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $4.78.

Coronado Biosciences, Inc is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.